CXCL13 and neoplasm: For example, in a recent study whole-exome and transcriptomic data for >1000 immune checkpoint inhibitor-treated patients across seven tumor types were combined with single-cell RNA-seq data from clonal neoantigen-reactive CD8+ tumor-infiltrating lymphocytes (TILs), to identify CCR5 and CXCL13 as T cell-intrinsic markers of ICI sensitivity (Litchfield et al., 2021).